Clinical Trial Update: Study Evaluating BeneFIX in Patients With Haemophilia B, Previously Treated With Plasma Derived Factor IX [Phase 4]

View source ↗

Summary

Phase 4 trial evaluating BeneFIX (recombinant factor IX) in patients with Hemophilia B completed; results posted in 2010.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hemophilia

Drugs mentioned

• BeneFIX (recombinant coagulation factor IX concentrate)

Snippet

Sponsor: Wyeth is now a wholly owned subsidiary of Pfizer | Conditions: Hemophilia B | Phase 4 | Status: COMPLETED | Results posted: 2010-06-29